Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Bum Jun KimHee-Jung JeeSun Young RhaHye Sook HanMin-Hee RyuSe Hoon ParkJong Gwang KimWoo Kyun BaeKeun-Wook LeeDo-Youn OhJi-Hye ByunDong Sook KimYoung Ju SuhHyonggin AnDae Young ZangPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2022)
In patients with HER2-positive gastric or GEJ adenocarcinoma, the objective response rate to second-line treatment with ramucirumab plus paclitaxel was significantly higher compared to patients with HER2-negative disease. However, an increased response to treatment was not associated with an improvement in OS.
Keyphrases